Percheron Therapeutics（PERC.F）株式概要Percheron Therapeutics Limitedはオーストラリアで新規アンチセンス医薬品の研究開発を行っている。 詳細PERC.F ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析意味のある時価総額がありません ( $4M )過去1年間で株主の希薄化は大幅に進んだ 株式の流動性は非常に低い 今後3年間の収益は年平均90.4%減少すると予測されている。 +2 さらなるリスクすべてのリスクチェックを見るPERC.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.00216.7% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-16m4m2016201920222025202620282031Revenue AU$2.3mEarnings AU$333.3kAdvancedSet Fair ValueView all narrativesPercheron Therapeutics Limited 競合他社GelteqSymbol: NasdaqCM:GELSMarket cap: US$4.5mSonoma PharmaceuticalsSymbol: NasdaqCM:SNOAMarket cap: US$3.8mCordovaCannSymbol: OTCPK:LVRL.FMarket cap: US$7.1mcbdMDSymbol: NYSEAM:YCBDMarket cap: US$8.0m価格と性能株価の高値、安値、推移の概要Percheron Therapeutics過去の株価現在の株価AU$0.00252週高値AU$0.01952週安値AU$0.0011ベータ1.021ヶ月の変化n/a3ヶ月変化n/a1年変化n/a3年間の変化-96.00%5年間の変化-98.70%IPOからの変化-96.00%最新ニュースお知らせ • Mar 16Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.174875 million.Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.174875 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 434,975,053 Price\Range: AUD 0.005 Security Features: Attached Options Transaction Features: Rights Offeringお知らせ • Aug 28Percheron Therapeutics Limited, Annual General Meeting, Oct 22, 2025Percheron Therapeutics Limited, Annual General Meeting, Oct 22, 2025.お知らせ • Nov 26Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 13.01854 million.Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 13.01854 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 135,231,746 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 27,500,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listingお知らせ • Nov 15Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million.Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 23,160,916 Price\Range: AUD 0.008お知らせ • Oct 23Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 25,000,000 Price\Range: AUD 0.08お知らせ • Oct 18Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million.Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 135,231,746 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 27,500,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listing最新情報をもっと見るRecent updatesお知らせ • Mar 16Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.174875 million.Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.174875 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 434,975,053 Price\Range: AUD 0.005 Security Features: Attached Options Transaction Features: Rights Offeringお知らせ • Aug 28Percheron Therapeutics Limited, Annual General Meeting, Oct 22, 2025Percheron Therapeutics Limited, Annual General Meeting, Oct 22, 2025.お知らせ • Nov 26Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 13.01854 million.Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 13.01854 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 135,231,746 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 27,500,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listingお知らせ • Nov 15Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million.Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 23,160,916 Price\Range: AUD 0.008お知らせ • Oct 23Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 25,000,000 Price\Range: AUD 0.08お知らせ • Oct 18Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million.Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 135,231,746 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 27,500,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listingお知らせ • Oct 17Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023, at 14:00 AUS Eastern Standard Time. Location: Minter Ellison, Collins Arch Level 20 447 Collins Street Melbourne VIC 3000 Melbourne Australia Agenda: To receive and consider the Annual Financial Report of the Company for the year ended 30 June 2023 (2023 Annual Report), comprising the Financial Report, the Directors' Report, and the Auditor's Report; to consider Non-Binding Resolution to Adopt the 2023 Remuneration Report; to consider Re-Election of Director Dr. Charmaine Gittleson; to consider Ratification of Prior Issue of Shares to Institutional Investors; to consider Approval for issue of Options to Dr. James Garner; to consider Approval of Employee Share Option Plan; to consider Approval for issue of Options to Dr. Charmaine Gittleson; to consider Approval of change of Company name and modification of Constitution; and to consider Approval of 10% Placement Facility.お知らせ • Jun 29Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UKAntisense Therapeutics Limited announced that it has received both regulatory authority and ethics committee approval to conduct its double-blind, placebo controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne muscular dystrophy (DMD) in the United Kingdom (UK). Following these approvals, requisite contracts are anticipated to be finalised for initiation of trial sites, expected during third quarter current year 2023.お知らせ • May 08+ 1 more updateAntisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023The Board of Directors of Antisense Therapeutics Limited announced the appointment of Dr James Garner MBBS MBA as Chief Executive Officer (CEO). Dr Garner will assume the roles as of 07 August 2023. This appointment follows the previously announced retirement, on 15 November 2022, of Mr. Mark Diamond from the roles of MD and CEO, with Mark's last working day 12 May 2023. To ensure continuity and leadership, Dr Charmaine Gittleson will assume the role of Executive Chairman, with immediate effect, until James is settled in his CEO and MD duties. James brings broad experience in drug development and commercialisation, acquired through regional and global roles in the biotech and pharmaceutical sector. His previous responsibilities have included leading phase I-IV clinical trials, product registration, reimbursement, and business development. He possesses strong executive leadership and management skills that have seen him achieve outstanding results over a twenty-year career in the Pharmaceutical/Biotechnology industry including roles with Biogen, Progen Pharmaceuticals, Quintiles (an international clinical research organisation) and as Head of the Unit Development Office, AP R&D with Sanofi in Singapore. Most recently James has served as CEO of Kazia Therapeutics Limited.お知らせ • Feb 15Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device AgencyAntisense Therapeutics Limited announced that it has received regulatory authority approval from the Turkish Medicines and Medical Device Agency (TMMDA) to conduct its double-blind, placebo controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne muscular dystrophy (DMD). As previously advised, the Company had submitted a Clinical Trial Application (CTA) for approval to conduct the Phase IIb trial in UK, Bulgaria and Turkey. This first trial approval by a regulatory authority is an important milestone for the Company in affirming the quality and acceptability of the Phase IIb trial design and critically, in providing the `green light' for trial initiation at expected high patient enrolling sites. The Phase IIb study aims to enrol and randomize 45 non-ambulant boys with DMD from multiple clinical trial sites in Europe and Australia. Following the initial six-month regimen of either placebo, 25 mg or 50 mg ATL1102 once weekly (blinded phase), participants will continue into a further six-month open label treatment period. Trial approvals in Bulgaria, the UK and Australia are expected to come through in a staggered manner depending on the respective regulatory agencies' evaluation process and timelines. The Company will make further announcements as and when material progress updates emerge. As per previous guidance, reporting of the results from the blinded phase of the trial is anticipated in First half of 2024.お知らせ • Feb 03Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMDAntisense Therapeutics Limited reported initial positive muscle functional data from a DMD mdx animal study assessing the use of the combination of antisense (ASO) to CD49d with a dystrophin exon skipping restoration drug. The use of the combination improved the specific maximum force of the extensor digitorum longus (EDL) muscle, a lower leg muscle, and the eccentric muscle force remaining following induced damage to the EDL. This functional data supports the potential use of ATL1102 in combination with dystrophin restoration drugs to improve therapeutic outcomes in patients with DMD. Under the collaborative research agreement with the Murdoch Children's Research Institute's (MCRI), six groups of DMD mdx mice (n=8 per group) were treated for 6 weeks with antisense oligonucleotide to CD49d (mouse equivalent of ATL1102), or control oligonucleotide mismatch or saline treatments, or the morpholino exon skipping dystrophin restoration drug alone and in combination. The muscle physiology of the EDL was assessed for force parameters including specific maximum force and the force drop following 1 to 10 eccentric (lengthening) contraction each involving induced muscle damage by the stretching of the muscle by 10%. The EDL is 1 of 4 muscles in the front of the lower leg whose function is to invert the foot at the ankle. Another of these muscles is the tibialis anterior (TA) on which the ASO to CD49d has previously reported a benefit in reducing eccentric muscle damage in mdx mice. The ASO to CD49d and morpholino exon skipping combination improved the specific maximum force (the maximum force corrected for size/mass and cross-sectional area of the EDL muscle) and both the eccentric muscle force remaining after a single and 10 repeated lengthening contractions with statistically significant effects compared to saline control. This combination after the 10 repeated lengthening contractions, also showed a significant effect (P<0.001) compared to the exon skipping drug used alone and the exon skipping drug used together with the control oligo. In addition, the ASO to CD49d showed a significant effect vs the saline and its control oligo. The morpholino exon skipping drug showed a significant effect compared to the saline control. A provisional patent application titled "Combination Compositions and Methods for Treatment of Muscular Dystrophy" is to be filed to cover the use of the ASO to CD49d and the morpholino exon skipping drug combination to seek protection of the combination of ATL1102 with the dystrophin restoration/exon skipping drugs to 2044, well beyond the patent life of the registered dystrophin restoration drugs. Notably the dystrophin restoration drugs have yet to demonstrate in controlled clinical studies a slowing of the loss of ambulation beyond use of corticosteroids, highlighting the clinical need for a more efficacious therapeutic approach.Further investigations are ongoing in the mdx mouse combination study to determine the possible mechanisms by which the combination approach is providing the observed functional benefits. Muscle RNA and protein samples have been isolated from the mdx mice quadricep muscle for analysis of the dystrophin levels in the muscle to determine if higher levels are seen with the use of the combination than with the dystrophin restoration agent alone. Cellular markers of inflammation and fibrosis including those observed in the ATL1102 DMD Phase II study, will also be assessed to elucidate the potential mechanisms that may be involved. Results from this analysis are anticipated before the end of the first quarter of current year 2023.株主還元PERC.FUS PharmaceuticalsUS 市場7D-42.9%5.3%1.1%1Yn/a44.3%28.7%株主還元を見る業界別リターン: PERC.FがUS Pharmaceuticals業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: PERC.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is PERC.F's price volatile compared to industry and market?PERC.F volatilityPERC.F Average Weekly Movementn/aPharmaceuticals Industry Average Movement9.9%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: PERC.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のPERC.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2000n/aJames Garnerpercherontx.comPercheron Therapeutics社は、オーストラリアで新規アンチセンス医薬品の研究開発を行っている。同社の製品パイプラインには、CD49dのアンチセンス阻害剤であるATL1102があり、デュシェンヌ型筋ジストロフィー、四肢帯状筋ジストロフィーR2、多発性硬化症、喘息、その他の炎症性疾患の治療薬として第IIa相臨床試験中である。また、同社の製品パイプラインには、成長ホルモン受容体を標的とするオリゴヌクレオチドで、成長ホルモン受容体の発現を阻害することにより、血中のインスリン様成長因子-Iホルモンの濃度を低下させるように設計されたアテシドーセン（ATL1103）、および過剰な成長ホルモンの作用に関連する疾患の治療薬があり、第II相臨床試験を終了している。同社は以前、アンチセンス・セラピューティクス・リミテッドとして知られていたが、2023年12月にパーチェロン・セラピューティクス・リミテッドに社名を変更した。Percheron Therapeutics Limitedは2000年に設立され、オーストラリアのメルボルンに本社を置いている。もっと見るPercheron Therapeutics Limited 基礎のまとめPercheron Therapeutics の収益と売上を時価総額と比較するとどうか。PERC.F 基礎統計学時価総額US$4.34m収益（TTM）-US$6.77m売上高(TTM)US$1.24m3.5xP/Sレシオ-0.6xPER（株価収益率PERC.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PERC.F 損益計算書（TTM）収益AU$1.74m売上原価AU$188.17k売上総利益AU$1.55mその他の費用AU$11.04m収益-AU$9.49m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.0062グロス・マージン89.17%純利益率-546.23%有利子負債／自己資本比率0%PERC.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 21:22終値2026/05/22 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Percheron Therapeutics Limited 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Jyoti PrakashEdison Investment Research
お知らせ • Mar 16Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.174875 million.Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.174875 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 434,975,053 Price\Range: AUD 0.005 Security Features: Attached Options Transaction Features: Rights Offering
お知らせ • Aug 28Percheron Therapeutics Limited, Annual General Meeting, Oct 22, 2025Percheron Therapeutics Limited, Annual General Meeting, Oct 22, 2025.
お知らせ • Nov 26Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 13.01854 million.Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 13.01854 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 135,231,746 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 27,500,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listing
お知らせ • Nov 15Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million.Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 23,160,916 Price\Range: AUD 0.008
お知らせ • Oct 23Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 25,000,000 Price\Range: AUD 0.08
お知らせ • Oct 18Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million.Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 135,231,746 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 27,500,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listing
お知らせ • Mar 16Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.174875 million.Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2.174875 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 434,975,053 Price\Range: AUD 0.005 Security Features: Attached Options Transaction Features: Rights Offering
お知らせ • Aug 28Percheron Therapeutics Limited, Annual General Meeting, Oct 22, 2025Percheron Therapeutics Limited, Annual General Meeting, Oct 22, 2025.
お知らせ • Nov 26Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 13.01854 million.Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 13.01854 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 135,231,746 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 27,500,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listing
お知らせ • Nov 15Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million.Percheron Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.185287 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 23,160,916 Price\Range: AUD 0.008
お知らせ • Oct 23Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 25,000,000 Price\Range: AUD 0.08
お知らせ • Oct 18Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million.Percheron Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 13.01854 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 135,231,746 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 27,500,000 Price\Range: AUD 0.08 Discount Per Security: AUD 0.0048 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 17Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023, at 14:00 AUS Eastern Standard Time. Location: Minter Ellison, Collins Arch Level 20 447 Collins Street Melbourne VIC 3000 Melbourne Australia Agenda: To receive and consider the Annual Financial Report of the Company for the year ended 30 June 2023 (2023 Annual Report), comprising the Financial Report, the Directors' Report, and the Auditor's Report; to consider Non-Binding Resolution to Adopt the 2023 Remuneration Report; to consider Re-Election of Director Dr. Charmaine Gittleson; to consider Ratification of Prior Issue of Shares to Institutional Investors; to consider Approval for issue of Options to Dr. James Garner; to consider Approval of Employee Share Option Plan; to consider Approval for issue of Options to Dr. Charmaine Gittleson; to consider Approval of change of Company name and modification of Constitution; and to consider Approval of 10% Placement Facility.
お知らせ • Jun 29Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UKAntisense Therapeutics Limited announced that it has received both regulatory authority and ethics committee approval to conduct its double-blind, placebo controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne muscular dystrophy (DMD) in the United Kingdom (UK). Following these approvals, requisite contracts are anticipated to be finalised for initiation of trial sites, expected during third quarter current year 2023.
お知らせ • May 08+ 1 more updateAntisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023The Board of Directors of Antisense Therapeutics Limited announced the appointment of Dr James Garner MBBS MBA as Chief Executive Officer (CEO). Dr Garner will assume the roles as of 07 August 2023. This appointment follows the previously announced retirement, on 15 November 2022, of Mr. Mark Diamond from the roles of MD and CEO, with Mark's last working day 12 May 2023. To ensure continuity and leadership, Dr Charmaine Gittleson will assume the role of Executive Chairman, with immediate effect, until James is settled in his CEO and MD duties. James brings broad experience in drug development and commercialisation, acquired through regional and global roles in the biotech and pharmaceutical sector. His previous responsibilities have included leading phase I-IV clinical trials, product registration, reimbursement, and business development. He possesses strong executive leadership and management skills that have seen him achieve outstanding results over a twenty-year career in the Pharmaceutical/Biotechnology industry including roles with Biogen, Progen Pharmaceuticals, Quintiles (an international clinical research organisation) and as Head of the Unit Development Office, AP R&D with Sanofi in Singapore. Most recently James has served as CEO of Kazia Therapeutics Limited.
お知らせ • Feb 15Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device AgencyAntisense Therapeutics Limited announced that it has received regulatory authority approval from the Turkish Medicines and Medical Device Agency (TMMDA) to conduct its double-blind, placebo controlled Phase IIb trial of ATL1102 in non-ambulant boys with Duchenne muscular dystrophy (DMD). As previously advised, the Company had submitted a Clinical Trial Application (CTA) for approval to conduct the Phase IIb trial in UK, Bulgaria and Turkey. This first trial approval by a regulatory authority is an important milestone for the Company in affirming the quality and acceptability of the Phase IIb trial design and critically, in providing the `green light' for trial initiation at expected high patient enrolling sites. The Phase IIb study aims to enrol and randomize 45 non-ambulant boys with DMD from multiple clinical trial sites in Europe and Australia. Following the initial six-month regimen of either placebo, 25 mg or 50 mg ATL1102 once weekly (blinded phase), participants will continue into a further six-month open label treatment period. Trial approvals in Bulgaria, the UK and Australia are expected to come through in a staggered manner depending on the respective regulatory agencies' evaluation process and timelines. The Company will make further announcements as and when material progress updates emerge. As per previous guidance, reporting of the results from the blinded phase of the trial is anticipated in First half of 2024.
お知らせ • Feb 03Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMDAntisense Therapeutics Limited reported initial positive muscle functional data from a DMD mdx animal study assessing the use of the combination of antisense (ASO) to CD49d with a dystrophin exon skipping restoration drug. The use of the combination improved the specific maximum force of the extensor digitorum longus (EDL) muscle, a lower leg muscle, and the eccentric muscle force remaining following induced damage to the EDL. This functional data supports the potential use of ATL1102 in combination with dystrophin restoration drugs to improve therapeutic outcomes in patients with DMD. Under the collaborative research agreement with the Murdoch Children's Research Institute's (MCRI), six groups of DMD mdx mice (n=8 per group) were treated for 6 weeks with antisense oligonucleotide to CD49d (mouse equivalent of ATL1102), or control oligonucleotide mismatch or saline treatments, or the morpholino exon skipping dystrophin restoration drug alone and in combination. The muscle physiology of the EDL was assessed for force parameters including specific maximum force and the force drop following 1 to 10 eccentric (lengthening) contraction each involving induced muscle damage by the stretching of the muscle by 10%. The EDL is 1 of 4 muscles in the front of the lower leg whose function is to invert the foot at the ankle. Another of these muscles is the tibialis anterior (TA) on which the ASO to CD49d has previously reported a benefit in reducing eccentric muscle damage in mdx mice. The ASO to CD49d and morpholino exon skipping combination improved the specific maximum force (the maximum force corrected for size/mass and cross-sectional area of the EDL muscle) and both the eccentric muscle force remaining after a single and 10 repeated lengthening contractions with statistically significant effects compared to saline control. This combination after the 10 repeated lengthening contractions, also showed a significant effect (P<0.001) compared to the exon skipping drug used alone and the exon skipping drug used together with the control oligo. In addition, the ASO to CD49d showed a significant effect vs the saline and its control oligo. The morpholino exon skipping drug showed a significant effect compared to the saline control. A provisional patent application titled "Combination Compositions and Methods for Treatment of Muscular Dystrophy" is to be filed to cover the use of the ASO to CD49d and the morpholino exon skipping drug combination to seek protection of the combination of ATL1102 with the dystrophin restoration/exon skipping drugs to 2044, well beyond the patent life of the registered dystrophin restoration drugs. Notably the dystrophin restoration drugs have yet to demonstrate in controlled clinical studies a slowing of the loss of ambulation beyond use of corticosteroids, highlighting the clinical need for a more efficacious therapeutic approach.Further investigations are ongoing in the mdx mouse combination study to determine the possible mechanisms by which the combination approach is providing the observed functional benefits. Muscle RNA and protein samples have been isolated from the mdx mice quadricep muscle for analysis of the dystrophin levels in the muscle to determine if higher levels are seen with the use of the combination than with the dystrophin restoration agent alone. Cellular markers of inflammation and fibrosis including those observed in the ATL1102 DMD Phase II study, will also be assessed to elucidate the potential mechanisms that may be involved. Results from this analysis are anticipated before the end of the first quarter of current year 2023.
